Results 251 to 260 of about 181,578 (308)

Ion Activation Methods for Top‐Down Proteomics

Mass Spectrometry Reviews, EarlyView.
ABSTRACT Mass spectrometry (MS) has emerged as a premier method used to characterize the sequences of proteins. Top‐down proteomics aims to capture the multiple sources of structural diversity reflected in proteins, such as those that arise from alternative RNA splicing events or the addition of post‐translational modifications. Tandem MS (i.e., MS/MS)
Jada N. Walker, Jennifer S. Brodbelt
wiley   +1 more source

Commentary: is trogocytosis relevant for chimeric antigen receptor-T cells? [PDF]

Oncologist
Toolabi B, Whiteheart SW, Munker R.
europepmc   +1 more source

Immunotherapy of chimeric antigen receptor NK cells: status and its promising future. [PDF]

Front Immunol
Wang F, Huang Z, Feng X, Shi M.
europepmc   +1 more source

Cancer‐Associated Fibroblasts: Central Players in the Plastic Pancreatic Cancer Microenvironment and Therapeutic Targeting

Organ Medicine, EarlyView.
Cancer‐associated fibroblasts (CAFs) are key regulators of the pancreatic tumor microenvironment. Through metabolic reprogramming, CAFs support tumor growth by providing nutrients and remodeling extracellular matrix. CAF heterogeneity, including myCAF, iCAF, and apCAF subsets, contributes to immune modulation and therapeutic resistance.
Ziyi Qin, Jinyang Ma, Rui Ju, Lei Guo
wiley   +1 more source

FAM168B identified as a novel candidate target for chimeric antigen receptor T cell-based cancer therapy. [PDF]

Discov Oncol
Pramanik S, Thaker M, Inoue N, Kim PS, Kutzner A, Manavalan A, Pramanik G, Heese K.   +7 more
europepmc   +1 more source

Beyond CAR-T and oncology: broadening chimeric antigen receptor technologies across cell types and diseases. [PDF]

Precis Clin Med
Liu X, Gao H, Yu J.
europepmc   +1 more source

Chimeric antigen receptor therapy for hepatocellular carcinoma

Seminars in Immunology
Lorenz Kocheise, Mohamed-Reda Benmebarek, Mitchell Ho, Tim F. Greten   +3 more
openaire   +2 more sources

Intein-based modular chimeric antigen receptor platform for specific CD19/CD20 co-targeting. [PDF]

Mol Oncol
Gonzalez-Garcia P, Moares N, Yi-He W, Luna-Espejo R, Fernandez-Cisnal R, Ocaña-Cuesta J, Muñoz-Miranda JP, Gabucio A, Fernandez-Ponce CM, Garcia-Cozar F.   +9 more
europepmc   +1 more source

Cytomegalovirus Infection After Chimeric Antigen Receptor T-Cell Therapy or Bispecific Antibody Treatment for Hematologic Malignancies. [PDF]

Transpl Infect Dis
Han J, Lim SY, Hyung J, Cho H, Yoon DH, Kim SH.   +5 more
europepmc   +1 more source

AMPK agonism optimizes the in vivo activation and antileukemic efficacy of chimeric antigen receptor T cells. [PDF]

J Immunother Cancer
Braverman E, Qin M, Ampudia-Mesias E, Schuler HT, Brown H, Murdych L, Titus A, MacLean A, Kanagala B, Wittmann C, Ramgopal A, Kemp F, Mullet SJ, Yang A, Poholek AC, Gelhaus S, Byersdorfer C.   +16 more
europepmc   +1 more source